pinakas_anapirias

38070 ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥΒΕΡΝΗΣΕΩΣ (ΤΕΥΧΟΣ ΔΕΥΤΕΡΟ)

1.1.1

. : . ( ).

A, 2, F :

- Cooley - ( )- ( ) (3 4

). . -

1) - -

………….. 0 %

2) - , Cooley.

., , , 6

, , , , ,.

: Hb , 2 F : =0-1%, 2=4-

10%, F=90-96%. . -

.- - -

: ……………. 50-80%

( ,

).- - -

. ………………… 20-40%

.3) H

ΕΦΗΜΕΡΙΣ ΤΗΣ ΚΥΒΕΡΝΗΣΕΩΣ (ΤΕΥΧΟΣ ΔΕΥΤΕΡΟ) 38071

………………. 20-40%

1.2..

, , S .

.1 :

: S. …………………. 0%

2)

: ( ) ,, .

.

., .

: - – …………… 40% -

- ………….. 67-80%

3)- ( S,

) - ( )..

1.3..

,.

.

1

:. .

……………… 0% 2

: , ..

:


( ) ……………… 20% ( ) ………………. 10%

1.4..

PIG-A.T ,

/

.1) , ,

………………… 0-20% 2)

………………. 40-60% 3)

………………. 60-80%

2.

2.1., ,

. ……................................................... 10%

, : ……………. 40-60%

2.2. ( )

- , , , ( ) .

-. HLA ,

.

:( ) (1-2 ): ………… 80% ( ) (

/ / ) : …………… 10-30% ( ) : ….…………….60-80%

3.

3.1 ,


. :. VIII IX .

, .

.

VIII IX .

( ) :

( ) ( >10%) ……..…………… 20%

( ) ( 1-10%) ………… 40-50%

( ) ( <1%) ………… 50-67%

,

3.2.

3.2.1. ( ).

1) ( <10.000/ )

:- : ………… 0-20% 2) :( ) ’ >50.000/ ,

…………… 0% ( ) ’ <50.000 / 20.000/( ) / .

………. 10-30% ( ) ’ <20.000/ , ( )

, 60 .

……….. 30-67%

3..2..2..

,.

( ) . ………… 0%

( )

…………. 20-40%

3.3. Glanzmann


. ADP .

………… 0-20%

3.4. Bernard-Soulier ,

..

………….. 0-40%

3.5. von Willebrand von Willebrand (vWF) -

. ,.

. :

: …….. 0-40%

4.,

/( . ).5.

:1)2)3)4) 5q 5)6)

’ . 1-4 .

( ) :

……… 20-40%

( ) : ………. 40-60%

’ . 5-6 .

……… 50-67%

6., ,

/ , . . .


( ) : ………… 0-20%

( ) : ……… 40%

- .

7..

………… 35-67%

8. ( )

( )..

:( ) ………………80% ( )( ) ………. 20-30% ( ) :

- ………… 30-40% -

…………. 50-80%

9. ( )

bcr-abl. :

1) ( )2)3) ( 2 3 ).

:( ) ,

,………………. ……… 20%

( ) :- (graft versus host disease) :

……..……….. 30-40% - :

…….. 50- 80%

10.

. :

( ) / : ………. 0-20% ( ) / : ………..35-67%


11.,

. :

( ) : …………… 0-20% ( ) , .( ) , ,

.

12.M.

. , , ( , ).

,.

:( ) : ………. 20-50% ( ) : …………. 40-60% ( ) .

13.

., ,

, ., .

,.

. ,.

: ( ) , : ………. …20% ( ) : ……… 40-67%

14. WALDENSTROM

IgM. , , , IgM ( >5 gr/dl).

: ( ) /……… 10-30% ( ) / ,( ) : …….. 40-80%


15..

, IgG, IgA, .

, , .

(MGUS, monoclonal gammopathy of unknovn significance).

:( ) MGUS ( ): ……... 0% ( ) : …….0-20% ( ) : ……...40-50% ( ) , ,( ) ….. 50-80%

16.

, , , .

( ) ,: .. ……….. .20%

( ) / / ……. 67-80%

17.

17.1. Hodgkin

.

( ) ……… …….. 50-67% ( )( ) : …….. 20% ( ) 1 / :1) : …….. 20-40% 2) (

/ ) : …….. 50-80%

17.2 M odgkin’s .-Hodgkin

. -Hodgkin .

1. :

( ) ,, : ………. 20%

( ) ,


: ……… 35-67% 2.

( ) ……… …….. 50-67% ( )( ) , ( ) : …….. 20% ( ) ,

, : …….. ..67-80%

( ) …….. 20-40%

(AIDS)

. - HIV.

, CD4 HIV RNA .

CD4 , (CD4>500/ l), (CD4:200-500/ l), (CD4< 200/ l) (CD4 <50 l).

HIV CD4 .

, ,, , , ,

.1 – ( CD4>500/ l)

, , , . -

, .. .

……………………………………10-20%

2 - (CD4 200-500/ l) ( , , ,

), ,, in situ ,

, , ,, .

CD4<350/ l /.

-

- .…………….40-50%


� ….67% 50%.

3 - / (CD4 < 200/ l) AIDS: P.jiroveci, ,

, , ,, Kaposi, , .

CD4<50/ l/ , ,

Mycobacterium avium complex, ,, , .

- .

( . . CMV , , / ).�

………………………………..…………………………………80- 80%.………………………………………………… 80%.

……………………………………….80%.

.

1. Nelson E24.1, D35.2 .

Cushing.. .

1

, , ..

ACTH ..

• –

1. , ( . Cushing)

� ……… > 67% [2 ]………………………………………………………………..20-30% [ ]2. ,

( . Cushing) � ……… >67% [3 ]…………………………………………………………………...30% [ ]


2. Cushing E24.0, D35.2 .

ACTH <10mm ( ) 10 mm

.1

, , , ,.

, ACTH ( ), 24 ,.

.• –

.�-…………………………………………………… 67% [2 ]-

, 6-18 , ’ …67% [2 ] 20% [6-18 ]

- ( )

……………..30% - ................50% (

( , )

3. E22.1, D35.2 .

< 1 cm ( ) > 1 cm ( ) (PRL).

.1

: , .: libido.

100-200 ng/ml. (< 1 cm). • –

( ) ( ).

�-

……………………………………………………………….10% - ( 90%) 5 …………………………………………………………67% [1 ]


- PRL ( )

…………………………..……. 10% [5 ]2

1 ,.

> 200 ng/ml. . (>2 cm).

• – ,

. ,.

� ……………………………………………...30%

4. – E22.0, D35.2 .

(GH) ( ) ( ).

·.

.1

, ,, .

, , . 20%.

. –

) < 2 cm , , 80-90%

.� …………………………………...67% [2 ]

) >2 cm 60-70%. 6 2 , ’ GH

� ……………67% [2 ] 20% [2 ]) >2 cm

. 10 .

� ………………..67% [ 2 ]……………………………………………………………...30% [10 ]2


1 , ,, . , , .

1 ..

• – )

� ……………..55-67% [ 2 ])

� …………………………………………….100%

5. E23.0, E89.3.

.:

1) .2) (Sheehan).3) .4) .5) , , , .

, ( )

..

1 ( )

- : , .- : , .

• – .

� …………………………………………...0% 2

( )

, .

4 3, TSH. –

.� ………………………………………….…..0% 3

ACTH ( )


,.

, ACTH. –

, , .� ………………………………………….20% 4

, .

– .

……………………………………………...20%

6. E23.2 .

:1) (

).2) ( )

3) ( ). .

1 E23.2

(5-25 L), , (5-25 L).

(<1005), ,.

. .• –

( , ,, , , , )

. ……………………………………………...10%

2

7. N25.1

(3-6 L). (3-6 L).

,.

• –


- , ( ), .

-.

� …………………………………..>67% [1 ]-� …………………………………………….100%

8. E06 .

.:

1. ( ). EO6.0 2. de Quervain ( ).E06.13. ( ). E06.3 4. Riedel ( ).E.06.5

.1

E06.0

, .

..

– .

..

. .� ………………………………..80% [1-2 ]2

E06.1

38-40 C, , , .

(>60 mm). -131.4 / T3, TSH.

– . 2 .

( ) .� ………………………………….. 30% [1 ]

3 .))) .

4 Riedel E06.5


( ) ,, .

• – . .

�- …………………………………………...10-20% - ………………………………………………….55%-

……………………………………………………………...67%

9. E05 .

:1) ( Graves – Basedow):

TSH .

2) : ) ..

1

100/min, , ,, .

4 3 ( 3). TSH. –

. 6 .

3 .� ………………………………30% [1 ]2

>100/min. . . .

.

4 3. TSH. • –

. 2 . ,

. 6-24 . (131 )

� ………………………………...30% [2 ]3

2.


• – ,

.………………………………50% [3-4 ]

1. ,. ( NOSPECS 0-1)

…………………………...20% [6 ]2. , (

)� …………………………...50% [4-6 ]4. ( , ), ,

, , .� …………………………...30-80% [3-24 ]5.� ………………………….…………….80-100%

10. E03 .

..

1

( ). ,.

4. TSH. . –

..

� ………………………….………………...0%2( ).

, , ,.

– .

,2-3 .� ………………………….…….30% [2-3 ]3

: 2, , , ,

, , .

4 3, TSH. ,( ).• –

, , .� ……………...50% [2-3 ]


4 E03.5

, : ..

4 3, TSH. .• –

- .…………….100% [2-3 ]

11..) . . D34 ) . C73

1. .2. .3. Hurthle cell (80% -20% )4.5.6.

.1

: <1 cm .

: <1 cm. :.

– .

.� …………………………….……50% [1 ]…………………………………………………………………...10% [ ]2

1. .2. .3. Hurthle cell .4. .

.

1 . –

1. . 10 90%. ,

. , (131 ) .�- ……………………………..20% (5 ) 10% ( )


- ………………………………………………………..50-80% 2. . .

.

- ……………………………………...20% (5 ) 10% - ……………………………………………………………80%3. Hurthle cell . .

- ………………………………………………………..20% - ……………………………………………………………90% 4. . .

(25%) ( ) 2).

.

) ……( ) 20% ) (<150)

………………………………………………………...50%) (>400)

………………………………………………………...100%3

, ..

– , ( )

. ,.

……………………………………………100%

12. E20 .

.

1. :. E89.2

2. .E20.03. . E20.8 4. ( ). E20.8

.1

. , Chvostek Trousseau, , .

7,5-8,5 mg%, , .


– D.

.…………………………………………..0-10%

2

1:

<7,2 mg %. –

D .�- ……………………………..100% - …………………………………………... 10-20% [ ]

13. E21.0, D35.1 .

(85%), (9%), (5%) (1%) (PTH). .

..

1

, .

11 mg%, PTH. –

.� …………………………………………..0-10%2

, , , ( ), .

11-15 mg%, , , , c-AMP, , (

),. Sestamibi . –

)1. ( <12 mg%)

.…………………………………………..0-10%

2. >15 mg% ………………………………………..60-100%

)1. .

………………………………...>30% [2 ]2.

.


…………….30% [2 ]3. .

………………………………..50% [10 ]4. .� ………………………………...100% [ ]

14. D35.0, E27.5 ( =C74.1)

..

..

1

, , , ,, , .

VMA 24 . ./ . scanning 131-

MIBG . –

1. , ,.……... 50% [2 ]

2. ,, .

……... >67% [1 ]

15. – .

. ( ) 21-

11 - ..

1 21- E25,

. –

. .� …….……………………………………….0%2

21- E25,

: , , .: , , .


, 17- ,,

. –

. .…….…………………………………...20-40%

3

2 , .

2 . –

.…….…………………………………...25-40%

4 D35.0

: .: , , .

, 17- ,.

. –

.� ……... 30% [2 ]5

C74.0

4 : , , .

4 :.

– ,

, , - . .� ……………………………….…………...100%

16. E26.0 .

( ).

.

. . . .

. , .

. –


1).

� ……... >30% [2 ]2)

.…….………………………………….……10%

17. ( Addison) E27.1, E27.2, A18.7, E27.3, E27.4

.. :

..

, , , , .

, , , , , ACTH.

– , .

� ……... 50% [1-2 ] ( , , )

( = E27.2).

� ……... >80% [1-2 ]

:�- ………………….20%- ……………………………… 30-40%

18. Cushing E24 .

Cushing. :1. ACTH ( Cushing).E24.2 2. ( Cushing). E24.0, D35.2 3. .D35.04. .C74.0 5. ACTH.E24.3

.1

Cushing E24.2

, , ,, , ACTH.

–


1. ACTH.

� …….………….. 50% ……………………………………………………..2. ,

.� ……... 50% [3 ]………………………………………….

2 ( Cushing) ( . 1.3.2)

3 D35.0

, .

, ACTH, .

.�-

………………………………………………………………... 40% [1 ]-

……………………………………………………………..20% [6 ]

19. D13.7, D13, C25.4, C17 .

() .

().

.1

: 90% . .

<50 mg%. <40 mg%. .

- ………………………………>67% [3 ]…………………………………………………………………...20% [ ]- ,

……………………………………………………………90-100%2• : 60%


, , , .

. ..

�-…………………………………………………………………..>67% [3 ]…………………………………………………………………...40% [ ]- (

)………………………………………………………..90-100%• : 60%

, .

, , , . ..

�- …………………...>67% [5 ]…………………………………………………………………...30% [ ]- ……………………………………...100% • ( Werner-Morrison « »

, , , ,.

, , VIP .�- …………………>67% [3 ]…………………………………………………………………...30% [ ]- ……………………………………...100% 3•( Zollinger-Ellison) >60%

, .

>100 pg/ml, ( ). 2

.�- ( . )- 2-

…………………………………………………………………30%- ………………………………………...100%

20. (MEN: Multiple Endocrine Neoplasia) C75.8

.


.. : 1) MEN I:

, , . 2) MEN II: , ,

, MEN I :.

1• D13.7, C25.4, D35.1, D35.2

. ( )

( ). ( , Cushing, ,

). Zollinger-Ellison.

/ . ..

- ( , )……………………………………………………….…………….50%

- …………………………………………………..70-90% -

……………………………………………………………………..100% 2• C73, D35.0, D35.1

( ). . ( . ). .

. ..

�, :

.............................................................................................................20% ( )

( )………………………………………………………………50-70%

1..

« » (TLC, FRC, RV)

( ). ( , . . .),


( – – ),, . . .

.

. ,, Ca (

) Ca ,

..

1

FVC/FVC pred 0,8-0,6 –

.� …………………………………………..5-10%2

FVC/FVC pred 0,6-0,5 –

.� ………………………………20-40% [1 ]3

FVC/FVC pred <0,5 –

.� ……………….50% [2 ]

2..

., ,

. :, , , , ,

, , - . ..

..

, ,.

.1

, .


: .

/ : , .: (FVC,

FEV1) FEV1/FVC>75%. : .: .

– .

� …………………………………………..5-10%2

.

. – .

: (, ( ).

/ : ..

:.

: .: .

– .

� ………………………………25-50% [1 ]3

.

. ,. .

: , ().

/ :.

:. .

:( ).

: . –

..

� ……………………………...67-80% [2 ]


3..

., , .

( :

) ( :

.).. ( ). 50

( 90%) .

.

1

3 ,.

1500 .

: , .: .

/ : .: FEV1/FVC: 0,70, FEV1/FEV1pr 0,60 FEF25-75/ FEF25-75pr 0,60. : .

– .

( . ) .� …………………………….………….5 - 10% 1 2 2

. 300 .

: . , .

/ : , – .

: FEV1/FVC 0,70 FEV1/FEV1pr 0,40-0,60.FEF25-75/FEF25-75pr 0,40 – 0,60

: , . –

..

� ……………………………...20-40% 1 - 2 3


.. 100 .

: . - ()

/ : – – – .

.: FEV1/FVC < 0,40, FEV1/FEV1pr < 0,40, FEF25-75/FEF25-75pr < 0,40: / (

). : .

– . .

, ..

� …………………………….………….50 -70% (2 )[ 3

( .). ,

’ .,

].

4.

.

(20-40 ) , , ,, , , , , ( ),

.: ) , ) )

. ) . Kveim .

:1) (SACE).2) -67.3) .4) .5) (30%)

..

1 0

- 0 / .- . ’

(80%) .


, , , ,.

: = . ./ : . . ,

.: . .

- .-

.-

. –

. 80% ,10% 10% .� …………………………….…………….5-10%2

-.

0 .. = . . .

/ : -. 1 2 .

: 1 2 . p 2 . VC.

DLCO. V (pons).

• – .

.� ………………………………20-50% [1 ]

.3

IV .

, , ·.

: .: ,

.: 2 3 .

.: 2 3

.FEV/FVCpr <0,5.

RV. TLC.

..


– .

� …………………………………………67-80%

5. – . ’

,.

:1. .2. ( ). 3. ( , . . .).

:----- ( . . )---

,

, ,,

,.

50% , 2

3 . ( ) 35% .

1 1 4-7

20 5 .

6. – .

.: 15 mm Hg,

. >25 mm Hg >30mmHg .

: ( )

..


.

, . . , ARDS, . . ..

1

.- ( , ), 2 3

.- 1 2 .

( ), , ,

( ).

.

(>25 mm Hg). –

.� …………………………….. 50% [1 ]

.2- 2 3 .- .- .- .

.

/ : ( ) , > 16 mm > 15 mm TLC.

– – ECHO-.

– ( –

) .� ……………………………...50-67% [2 ]

.3

2 .

/ : , 2 ,, .

. –

. 5.

�


. . 80% 2 .

7..

/,

(PaO2<60mmHg) , , . (PaO2<60mmHg) (PaCO2>45mmHg)..

.1• pO2 = 80-60 mm Hg.

, . .• PaO2 = 80-60 mm Hg PaCO2 = 45-50 mm Hg.

, pCO2.

• – .

� …………………………….. 50% [1 ].

2• PaO2 = 60-45 mm Hg.

1 – – . .

• PaO2 60-45 mm Hg PaCO2 = 50-70 mm Hg. ,

..

– .

.……………………………...50-80% [2 ]

3• pO2 45 mm Hg.

, 2 –

– – () – –

. ,. (

) .• pO2<45 mm Hg pCO2>70 mm Hg.

2 ., , , ,

..

–


.� ………………80% [2 ]

8..

.,

, , , , ( ).

. , , ,.

. . 0: .

Mantoux . 1: . Mantoux . 2: Mantoux , .

, . 3: .

, , , Mantoux.

4: . .Mantoux . .

. 5: .

..

. 3,

:1.

, .,

2 5.

2.,

, 1/3 ,.

4 cm. 3.

., ,

..

1


• – .

.

1 5-10% .2

– .

.�

1 10-20% .3

• – .

.�

20-25% .

.4

–

( . ., ).� ……………………………………………..80%

.,

.

9..

.,

. ,.

, ,.

,( )

..

1: ,

, ( ). –


.. .

� …………………………………………5-10%2

: .

( ). –

. .� …………………………………………20-40%3

. . pCO2 pH. .( ) –

. > 120 min.

� …………………………………………50-70%

10.

.,

, ., .

.,

.

, , , .: , ,

.: « ».

,,

, . –

,.

� ………………………………..5-15% [1 ] ( ,

) ( , . . .).

11.

, .

.


, , , .,

.: .

: . –

..

� ……………………………….5-20% [ ]

12.,

75-80% , 20-25% ’

..

( )1.2.

(F P) :1.2.3.4.5. ( , )6.7.8. (Pancoast)

: ) , ) , ).

�-Ca .....80% (2 )- Ca ……………………………….80% [2 ]- Ca

……………………………………...67% [3 2 ]-Ca (

80% 3 67% 2 50% .

- Ca …………...80%

13. 8% . 50%

., , (

). ( , , )

.


.

– .

.�

35% 67% ,.

.

.................................. 50% ( ') (

).

( ).

..

:

: , , ,.

: , ,.

: , ,.

( ).

, ,- ,

.

: - - - - -


- -

, ,( )

.,

. , 4% 10% .

.

/.

..

.

..

libido.

( ), .

, n-CPAP (nasal Continuous Positive Airway Pressure)

,

.

1

, : / 10 30

SatO2 85% ( )


/ 30 60 SatO2 80 84% ( )

/ 60 SatO2 80% ( )

: n-CPAP .

.....................................................5-25% (1 )

2

. (

- ) .: .

: , , ( . . . ).

3

2 , 3 (>100%, , )

’ Pickwick. :

........................................................67-80% (2 )

1.

( , , , ), (

).1.1.

1.1.1. 50 /1

..

1.1.2. ..


1.1.3. –

1.2.1.2.1.

………………………………………………………..0-5%1.2.2.

………………………………………………………..0-5%1.2.3.

:1)2) .

,,, …………….....…….…..………………………...0-10%

……………………………………………….…20-30%.

1.3.1.3.1.

.

,, , , ,

, 10-30%. ,

. ………………………...0%

1.3.2.( )

.

, ( ).

,.

: 1) PR 120 msec 2) QRS , ( )

3) ST-T.

……….…………..0-5%

……………….……..25-50%


,,( ), 67% 1.3.3.

, (240-400/1 ). 300/1150/1 .

F ( ).………………………………………………..……10-20%

1.3.4.,

.

……………………………………………0-10% ……………………………………….………….15-25% (ablation) ……………...0-25%

1.3.5. QRS

100 200 1 .,

.….………………………………………………….50-80%

1.3.6.

. – ,

( ) (ICD) .

1.4.

1.4.1. -- 1 : – .- 2 : ) Wenckebach, P-P ,

2 P-P. ) Mobitz II,

- 3 :

……………………………………………………..……….0% , ……….15-25%

1.4.2..

1.4.3.

. 35-60/1 .

P , AVF.

………………………………………………………..15-25% 1.4.4.


1.4.5. ( ).

P-R . .

.: ) Mobitz I, ) Mobitz II

2 ……….………………….……..….67-80%……………………………………………………15-25%

. ( ),,

30 40 1 . .

………………………………………………………..80% …………………………………………………………..15-25%

1.4.6.,

. : , ,

" – ".

…………………….…………………………20-50%….……………………….………………………..67%

………………………………………………………...15-25%

1.5...

.

1.6.

……………...………………15-25%

:1)2)3)4) .

1.7. (ICD)

.


…………………………………….50-80%

2..

., ,

.,

ST (NSTEMI - non-ST elevation myocardial infarction), ST (STEMI - ST elevation myocardial infarction) .

2.1.

Canadian Cardiovascular Society :

: - .

.: -

, ,

. , (100-200 m) ,

.: -

1-2 , .

V: - .

:…………………………….…………………..……..35%

:………………………………….……..……………………..………………..…...50%

:……………..……………….………………..………………..…67%

IV: …….……….……..…80%

( , ,. . .).

2.2. 2.2.1 ( )


, .

…………………..……………….….…..35-50% 2.2.2 PRINZMETAL

………………….…………………...…..35-67% 2.2.3

..

:1.2. ST 3.4. ,5.

.

……………………...…………..25-40% 2.3. ST (NSTE-ACS)

, ( ),

ST (NSTEMI)

.

2.4. ST X ST (>20min).

:1) 6 .2)3) .

……………………………..…….…………80%..…………………….….…………67%

:) – ) – ,, Tl201 , stress echo )

:- 50% ………………………….….35% - 50% .…………………..50% - 35-50%, ..........................……….…….50% - 35-50%, …….….67%- <35%, ................……………..80%


- ……………….........……………….50-80%

2.5.2.5.1

( STENT) .

- ………………………………..….. 67% - : :1)………………………………………………….…..……………….....20-30%2)

) ………………….……….………….50%) ………………………………………..67%

3) …..……….67-80% 2.5.2

.

- 1 .....……….………………………………….. 80% - 2 ………………………………………………67% - : :1)

………………………………………………….…..……….....35% 2)

) ………………….……….………….50%) ………………………………………..67%

3) ……..……….67-80% 3.

3.1.

,,

..

4-6 cm2.

( > 2 cm2)………….………...…5-10%

- ( 1,5 – 2 cm2 )……………...…………..35%

- ( 1,2 – 1,5 cm2 ).………...…………..50%

( < 1,2 cm2

20 mm Hg)…………………………………..……………………….…………67-80%

100 mm Hg……....80% ( )

……………………………………………..…………...…..20-35%………………………………….67-80%


……………………...…..……………40%…..………….…...67-80%

3.2.

., ,

-,

, .

.

,……………………………………………………………….………..0-5%

, ,

……………………………………………………………………..15-35% ………………………………….50-67%

- , …………………………………….80%

………………..………………20-35% …………………………………………..…….……………...67-80%

. ……………………...80% 3.3.

.,, ,, .

0.5 cm2. , , (

).

)

1,5-2 cm2

< 25 mm Hg……5-10%

1 – 1,5 cm2

25- 40 mm Hg… 50%

< 1 cm2

> 40mm Hg……....60-80% ) .

……...…………………….20-35% ……………………….…………………………..……………67-80%

3.4.

.,

( ).

) ……………………………………….…..5-10% ) . < 60 mm >55%……….......20-40%


) . > 60 mm >55%….. … 50-67% ) . > 60 mm <55%………......67-80%

( )

, . ……………….20-35% ………….………………………...67-80%

,.

3.5.

. ( )

( ,, ),

.

) …………….…………………………….20-35%) ……………………………………………...67-80%

()…………………………………………………………………….…20-35%

3.6.

.,

, . .:

. ..

) <5 mmHg > 1,5 cm2…….…..25-35%

) >5 mmHg …………………..…………………………………………………….50-67%

( )…..……20-35%

3.7.

.

.,

, ( ,

).

( )


4. 0,9% .

10% .

: ,, , ,

, , Fallot . , ,

.

4.1.

,. :

.

mm 2-3 cm.

. (Eisenmenger). 40

1) , 2) 3) – – Eisenmenger.

:,

……………………………………………..………….………….10%,

, 50% ………………………………………..35-50%

, 50%

Eisenmnger……………………………………………..…...…80- >80% (

).. ………………………………………….10%. -

……………………………………………….………….………...35-50%. ………...….……67-80% .

,, , ,

.


…………………………….…………..67->80%:

. ……………………..………...………...10-20%

. ……….……………67% .

.. –

.. Eisenmenger

.

……………………………………………………………………..35-50%

………..……………………..67-80%

4.2.

mm2 cm2 ( ).

,.

1 cm2/m2 , ( )

( ).

Eisenmenger .

( 1 cm2/m2

)…………………………………………...………..…………10% ( 1 cm2/m2 )

, (), ,

(Eisenmenger)………………………………………………….……………....67->80%

.) …....50-80%) ………...20-35%

4.3., .

( ).: , ,

, , , ,.


.

50% ……………….………...5-10%

50% ………………..….……..…35-67%

………………………..……………...….67->80%

…..………….….…25- 67%4.4. ( )

.( Eisenmenger)

, .

. :: 1 cm,

/ 2 …………………………..……………………..…….…...…..25-50%

: 1 cm, / 2, ,

…………………………….………….……67-80% Eisenmenger…………………………………..……………...…>80%

(

) – –.

4.5. (95%) . (25%)

.

( 1-2 mm) ,

.

, .

: ( ,

),

……………………………………………………………………….…35 - >80%.:

, ( ),


. . .…………………………………………………………………………….…...10-35%.4.6.

,.

,, ,

. 2 cm2/m2 .

……………………………………...…..……...10-20% ( 50 mm Hg)…………….35-50% ( 50 mm Hg)..…….…67-90%

( , ,)…………………………………...20-35%

4.7. FALLOT Fallot 1888 : 1)

, 2) , 3) 4) .

.: , , , .

20 .. 90% .

:, .…..…50->80%

. …..…………………...…….………..5-35%

. ……….…………………….…..……..50-80%

4.8.:

1) :.

,.

…….………………………50-80%2) :

.( ) .

.3) :

, .


, Ebstein, .

.

( )…………..………..………..35-60%-

……………………………….….67 - >80%

…………………………………………..………………..…….35-70%

4.9. EBSTEIN , « »

.

..

.

……………………………....………….……..…67 - >80%,…...50-70%

4.10. , ,

( )..

………………………………………..…..…………………….50-80%

5.

.:

1.,

2. , ( )

,, , AIDS, / .

3.

4.5. ’

5.1. ( ) , ,

,.


,, , ,

, , 2-8 , , .

- 50 mmHg…………………………..…………35% - 50 - 70 mmHg……….………………..…….…50-67% - > 70 mmHg…………….………………..…….…80%

’.

5.2.

.

, 1.4.6

6.,

7.,

.

8.:

) ().

) ().

,

8.1.

. , / , /, /

.

- > 55%.............................................................20-35% - 45- 55%. ............................................................50% - 35-45%...............................................................67% - < 35% ................................................................80% 8.2.

(HCM: hypertrophic cardiomyopathy) WHO/ISFC / .


.,

..

, ,.

., ,

. (15-20%), ,

40-50 . .

- ……….………………...…………35% - ( , ,

, ………………………..…..…67 – 80%

8.3.

,

.…………….…………………………………………..…80%

8.4. /

(ARVC)

..

1:5000 , ,

.. 50%

( , , ), « », 1986 .

( 2%) , ,

,.

.

- …………………………..…………………………….……..50 – 67%- ……………… …………………………..…..…………..80%


9.9.1.

,.

, , ,, ,

, ,

6 …………………….……………………………….....80% 6

( , ,) . :

- .

……………………………………………………………………………….……….0%- .

.……………………………..…..………..………….....80%

- 6 ………………………………………………………..…..67% 6 , . (

).- ( )

…………80– 90% - (

, , , , ) 35% .

9.2.

,.

.

.

:--- ( )- ( ,

, )………………..…………………………………...…50 – 80%

9.3.

.


.,

.

, .

.: …………………………..…..…10 – 80%.

9.4.

. ( ),

. 40% (40%) .

- ( , , ,)………………………………………….…………..………….......67 – 80%

- …………… .50 – 67%

10.

. 80% .

10.1.( – – – - –

– – )

(50% ). 75% , 20% 5%

.

- ………………..………...25 – 80% ……………………………………0%

., .

.

.

,.


( , ).

10.2.

. ,.

.

.…………….……………..…………… ……………..80%

( , , )

………………….………………………………….….80%

11

( ).

( , , , , . ). – –

( ) ..

12, ,

. – (1964) 4

. : H .

.

: . .

V : . .

.

13. /


(IV) .

(52%) (40%).

.

- ……………………………………………….……80%

- Zenker

– .

. .

( )……………. 0%

.

( ). ..

Heller.

– . .

( )……………. 0-10%

( , . .)

– ,

.

……..

– .

- ( )


3-4 .. .

……………. 0%

.1. HCl

2. ..

3. ..

– .

. 1

–

.

� ……………. 0%

21 . .

, .

–

.

� ……………. 5%

1 . Barrett. . Barrett

( ).

–

.

� ……………. 0%

2. ( )

� ………

3.


� ……… 0-20%

–

. .

� ……………. 0-15% (

- . ( , )

� ……….

.: ,

.1.

.2. : ( ).3. : Menetrier, Zollinger-Ellison. 4. : ,

.

1

1. : ..

2. : .( ) ( . 12)

.3. : , .

1.2. , , ,

, .3. , , HCl,

.

�


- :…… 0%

- ( , .12) ……0%

- Menetrier: ....0% - Zollinger-Ellison: ( )

:

.

1

. : , ,.

:

�- 2-4 ….. 0%

- ……………30% [30-40 ]

2�- ……………………...….50% [2 ]- ……. 50% [2 ].

– .

.:

. :- ( , ,

, , Peutz-Jeghers) - – ( ,

, GIST- )

. ( – – ). 95% .

: ,, .

.


1.

:.

. ( ). ( ), .

• –

. ( ).( )� ………………..50% [2 ] .

2.

(GIST) : ( )

� ………………..0-10%

.

, , .

. ( ).• –

. . .� …………………………………………..….70 – 100% ( 5

). 5- ,.

2: ( , , )

• –

. .� ……………………………………...……………100%

( ).

,.

, .


: ,.

.

• –

.� ………………………………………………..…….0%

.. ( ,

, ) ( , , – GIST: , ).

Peutz - Jeghers .

.

1

. : , ,.

. :1.2. ,3. ( , ). : , , .

( , MRI ),, .

. Peutz – Jeghers: ,. ( )

– .. : .

. 5 - HT (5- ).

1. (flush).2. ( ).3. ( , ).4. ( ).- : .

• –

. : . .� ………………………………………………..…….0%

. : . .. ( ).


� …………………..67 - 80% ( . 6)

. - GIST: Imatinib. �

…………………..0% ………………………… 67 - 80% ( . 6)

. Peutz – Jeghers: .

� ………………………………………………..…...0%

. : ,�- , ……0-30% ( 5

)- ………………………...…50 – 70%

., ,

( ). . –

Crohn. .

1 . .

(1-3) ( ) ..

.( )• –

. 1-3 .

� ………………………… 20% ( )

2

4 – 6 .

( )..

• –

.� ………………...40% [2 ].

.


3 ( )

- 8-15 , , , , ,

, .

, , , , . ( ), .

. :, , , , ( 10- ).

. :: , .

: .: , .

: , , .

• – 2-4%. .

,, . ,

10 .� ………50 - 80% 1 . ,

0-10%, 35 – 50%. - (

)- ( )

Crohn .

, .

. 10 - 40 .

: 40% - , 25% , 25% . 15% .

..

1

..

1.2. ,3. ,4. ( ).5. ( , )


.1.2. ( , , )3. – ( , )4. – ( , )5. ( )6. ( , )7. ( , )8.

: ) , ) ( ,), ) , )

) .

• –

’ ,.

�- ( . . 6)- …….…….…………… ……..60% [2 ]- ………………………..…………………………………………..0-10%

- .

. ( )

..

. ..

.1.

. , , . – Zenker.

2. 12/

.3.

..

4. –

, : , ,, .

5.

.


: ,.

,.

• –

..

..

.� , . .

..

6 .: , , ( , , ,

), ( , ), , .: A, B, C, D .

..

1.

., , , , , ,

.

, , . IgM IgG ( -HAV IgM -

HAV IgG). HbsAg HbeAg,-Hbc IgM, DNA (HBVDNA). D

.- DV . C

. -HCV RNA (HCVRNA). - V IgM

..

.

• –

. 3-12 , .

, C, .

� 80% [ - 2 ]


2.)

: .

, HbsAg, HbeAg -Hbe HBVDNA (<2000-20000 IU/ml).

( . . ,, , , ).

.

• – .

� ……..……..……………………………………….0%

)

( . . ,).

.

, HBVDNA (>2000 IU/ml) , HbsAg. Hbe (HbeAg )

(HbeAg ) -Hbe..

.. - .

• – , .

.

� ……… ..….30% ….0%.

) D

. .

, HbsAg, -HDV . To HDVRNA , .

.

. ,.

• –


..

� ……… ..….30%. ….0%. …. 10-20%.

) C

. , .

, -HCV . To HCVRNA .

.

. . 6 ( 2 3) 12 ( 1 4).

• – . ,

.

� ……… - ..….30%. ….0%.

…. 10%

)

, , , ,.

, - (IgG), ,. - ( , SMA, LKM1).

.

. - ..

• – .

.. ,

.

� ………20%, ….10%.

( – ).

:


) ( )) ( )) ( ))

.

1

. ( )

.. ( ). 20%. 20%

,.

• –

, , .�- (6 ) ………....…………………….…60 - 80% [4 ]- . . 6.

..

• – .

� …………....…………………… …..60 - 80% 4

.

. : , ( ), , ( ,

), ( , Wilson, ),. .

.

1

,. ,

( , , ).

- – – - - .- / .- .• –


50% 10 . 90%

� …………....………………………………… 10-20%

2 ( )

- , , , libido---- , ,- ( )

, , ,.

1.2.3.4.5. , -6.7.

• –

. 2 . .

� …………....…………………………………67 - 100%

.. ,

( – ),.

, ( )

.

1

--

:


1.2. ( )3.4.

• –

� …………....……………………………………… 0%

. 6

2

: 1) , ,, , 2) 3)

.• –

: ..

� ……………..60% ( 3 )

.

( ) ( - )..

( ), C .

( , ).

.

1

1..

2. – – 3.4. -

1. 1- ( )2. ( , GT, , )3.7. i.v. 8. , -9.


• –

. – – – .

� …………....……………………………………...100%

.. 90%

..

1.

• –

.�- …..…....……………………………………..0%- ….. 0%, . . 6.

. . . 6.

2

1. ( , - / ,).• –

. .� …………....…………………… .30-60% [15 ]

2. ..

• –

. .� ( . . 6)

3. . ., , , .

• –

. .� ( . . 6)

4. . . .• –


. .� ( . . 6)

5. ( , , ,).

• – . .

.� …………....………………….…………30-60% [15 ]

6. . , .• –

.7. . , , , .• –

.8. .• –

. ( ).

� …………....………………….…………80-100%

( 5 .).,

. .

.: ,

, , , ,, ( , Kaposi,

, . .).

�- ……… 50 - 67% [1 ]. , 10%

.- , C D ……..

, C D .- …………..

.- ……………………. 80%


( , ).

: , , .

.:

.: – ,

.: ,

( ), ( , , , . .),( , , , ).

(70%)

: ) ) – ..

1

( ), , , . :

, , , , , shock.

- . ., . . .

, . . ,.

�- ( ): , 50% [1 ]- - : . ,

( , ) 50% [1 ]- ( >8-10 .,

) 35-67% [2-3 , ]

:- .- .- .- .- .- .

:. , .

�- ( ) (

)…………… 0%. - ( )


- , ……………… 35-67%

.:

1. ( ).2. , , -IPMN.

.3. ( – – ).4. .

.

1

. .

. (>10 .) ,.

,.

• – . . .

� ………………………………………………….0%. . .

� ( . . 6)

2

– – ..

..

: , ,, NaCl .

�- . . : ( . . 6) - . …...………………………..80 – 100%

. 90% , 10% .

.

1

’ .1. .


2. , .3. , .4. .5. ( ).6. .7. .8. .9. ( ) .10. ( ).

: , ( ), - (ERCP).

• –

. 6 .� …………………………………………………….100%

, ,.

() ,

.

................................................................................................................ 0%

Turner ( )

. (1.8.2., 1.8.3. 1.8.4.)

.

..............................................................................................................0-5%

1 : (Ca in situ) .........................................................................................................

10-20% 2


2 :.........................................................................................................

40-50% 2

3 :

...............................................................................................................67% 2

4 : – V ( )

( V)

...............................................................................................................80% 2

( V)

..............................................................................................................0-5%

.

................................................................................................................ 0%

.

- ................................................................................................................... 30% ................................................................... 70%

- , , ..................................................................................................... 70% - ................................................................................................................. 80% - V ................................................................................................................. 80%

2 .

.................................................................................................... 67%

1 : – ..................................................................................................... 40%

2 : – IV ..................................................................................................... 80%

2 .


Stein-Leventhal

............................................................................................................... 0%

1 : 40 :

............................................................................................................... 0% 2 :

40 ................................................................................................... 0-5%

:

- , 45 ............................................................................................. 0%

- , 45 ................................................................................................ 0%

- 45.............................................................................................................................. 0%

- 45 ......................................................................................................................... 0-5%

:

- & .............................................................................................................. 67% 2

- & IV ......................................................................................................... 80%

KE1.

.( ), ( ) (

). 18,5-24,9 kg/m2, 25-29,9 kg/m2 >30 kg/m2 ( , 30-34,9 kg/m2 1

, 35-39,9 kg/m2 2 >40 kg/m2 3 )..

1 30-34.9 kg/m2

: ………………………………………….. 0-5% 2 35-39.9 kg/m2:

,: ………………………………………… 10-20%


3. 40-50 kg/m2 :

, ,

: ……………………………..….. >50% (2 ). 40-50 kg/m2 (

, , ).. >50 kg/m2:

, ,

: …………………………...……… >67% (2 )

2. ( )

..

1 ( 1 2) .

: …………………………,..………… 5-10% 2

( 1 2) (, )

: …………………………,..………… 10-20% 3

( 1 2) ( , ,, , , . . .)

( :)


.,

( . . , , ),, ,

,.

.

,- ,

. , ,,

.

:

( , – )

( )/

//

-aposi

()

L40O -

,, , ,

. (2 -3 )


.. ,

( , ,, ). ,

().

, .

, (),

, ( , ,

) .

, , . ( ),

3 , 20% 50% ( ,

). ( PASI score 10, ), 6

, 50-80% [12-24 ].

, .

L20 -

, ,. 3

( , ).,

, . ,

.,

, .. ( ,

, ) ( ,, ). (

, ).

• –

. Gram (+) .

.


() 3-6

, , 20% 50% ( 1-

2 )., 3

, 50-67% [6-12 ].

.

’ ( [L23] [L24] )

- .

’ ., , , ,

. , , ,, , , .

• –

. .

. ,.

, ’ (>2-3 / ), ,

( , ) 3 , 10-40% [12

].

L43-

.

, , ..

• – , ,

( )..

�


,, ,

3-6 . (1-2 ) 20-30%

.

L73.2-

( , ).. ,

. . ,.

, , ,- F ,

.• –

,, .

, , - .

.�

,, 20-50% ( 2-3 ).

L10-14

L13.0 [ DUHRING] -

,, , .

., ,

. –

. ( ).

.

, 6 ,

20-30% [1-2 ].

L10 ( , , )


-, ,

. ., ,

( , ).

..

• – / ,

, (

).,

., .

�

, 20-50%. , >67% ( 1-2 ).

L12.0L12.1

- .

/ ,. 60-70

., .

- ( , ,)

.

. –

,,

.

., , ,

, , ( ).�

25-50%, .

6- , , > 67% ( 1-2 ).


L94.0 ( )-

, , ,. , ,

, , .

• – .

(Raynaud), .

,.

. .,

.

, , ,. ,

,.

�,

( 20-40% ). ,

( ).,

> 67% ( 3 ).

M34.8 BUSCHKE -

.

.. .

–

,, .

25% 50% 1 – 2 - .


Q80-

(). ,

, , ( Netherton, KID).

-.

( ).

• –

( )., , , ,

,.

,, .

’

.�

,, 5-20%.

67%, 67%,

- 3-6 , > 67% ( 2-4

). ( ).

Q82.1-

,( ), (

, ) (, , ).

DNA . 5

DNA ..

,.

• –

., .


( ),

.�

, >67%, .

Q81-

. ,,

.. 3

( , ). ,, ,

.,

.• –

.,

. , (>

50% 35 ).�

, 5-20%.

, 50-67% ( ).,

>67% ( ).

Q85.0 von RECKLINGHAUSEN -

, .,

( ).

( ) ,- . ,

, , .. ,

. –

., .

..

�


, 10-20%.

, , ( . ).

E.80.0 ( ,)

80.180.2 ( , )

- (

). ,,

., , .

: 1) : ,, (

( - ) ), 2) :, , ,

, ( , )., , .

’ , 3) :( ), ( , , ),

( , , )., 4) : ,

, , 5) :, , ,

, . ..

.• –

( ). .

�, 50 >67%

. , 20% 50%

.

Q82.8 ( Meleda)

-


, ,,

. (

)., , ’

, , Meleda.

• – ,

.

.�

320-50%.

C84C84.0C84.1 SEZARY

- .

.. ,

. . ,, , , ,

. –

( : < 10% , : > 10% , :

, : , :, IV : , IV: ). Sezary:

- ..

.

( , ,, ).

,

.

1


..

– 1

, .. .

� ………… .…5-10% [ ]2

. ..

, , . –

. . ...

� ………………………………...…20 - 50% [2 – 3 ]3

,,

, , . Sezary. .• –

..

.� …………………….80-100% [2 – ’ ]

C46 KAPOSI (ME )-

,,

. (> 60 ).,

., ,

. ,, , , .

.,

( )..

–

. ( ), ,

. ( ).

�


, ,, ,

25-50% [1-2 ]. ( ),

, > 80% [2-3 ].

C43C51-52, C60.-, C63.-

-

.,

. 30-60 .

,.

. , ( > 1 mm)

. Breslow, - -

( = , =, V= ).

, 5 > 80%. ,

(5 30-70%). (), 2 .

–

. 1-12

.,

.�

,,

. , 20-50%( 1—2 ). , 80-100%.

C44 ()

- (

)


.,

., 5-10%

( ,).

–

90%. ( , ) ( ,

) (, Bowen in situ ).

(10-20%) ,, ( )

. ( ,

, , , ).�

,,

., 20-50% ( 1—2 )

., 80-100%. ,

,, Merkel.


. ,.

..

:

1.

2.3.

, , :

1. (International Classification

of Diseases/ICD), ( . . .),,

,. , ,

(ICD-10) 1992.2. ICD-10 3.

.

., )

) ,.

0 4, 0 ,4 1-2

.

0 – 1 – 2 – 3 – 4 –


0 4, 0

, (Global Assessment of Functioning, GAF), 4

, 1-2 .

( GAF) 0 – (GAF 81-100)1 – (GAF 61-80) 2 – (GAF 51-60) 3 – (GAF 31-50 ) 4 – (GAF 1-30 )

:

% = [( × )I – ( × )II] × 100/( × )I

=I=II=

. ICD-10

(International Classification of Diseases/ICD), ( . . .). , ,

1992.

ICD-10 :

1. :

(Alzheimer, Pick, , ,Creutzfeldt-Jakob, Huntington, AIDS . . )

( . .): 50-80%

(deliria) . .

,


, ,.

. .: 50-80%

2.

: , , , , ,, ,

.:

. .

. .: 35-67%

. .: 35-67%

( ) . .: 35-67%

:/ , . .: 50-80%

. .: 50-80%

. .: 50-80%.

3. ,:

. .: 50-80%

. .: 50-67%. .: 50-67%. .: 35-50%

. .: 35-67%

. .: 35-67%. .: 35-67%

4.


. .: 35-50%. .: 35-67%

. .: 35-50%

. .: 35-67%

( , ) . .: 35-50%

( ,)

. .: 35-50%

5. ,

,- . :

. .: 20-30%A . .: 20-30%A . .: 30-40%K

. .: 20-30% E . .: 20-30%M . .: 20-30%

I -. .: 30-67%

O . .: 20-30%. .: 30-67%

. .: 20-40%- . .: 20-40%- . .: 30-50%- . .: 20-40%- . .: 20-40%- . .: 20-40%- . .: 20-40%

Ganser . .: 20-40%. .: 30-50%

. .: 20-40%


. .: 20-40%. .: 20-40%

. .: 20-40%. .: 20-40%

- . .: 20-40%

6.

:

( , ). .: 30-67%

. .: 20-40%

. .: 20-40%, ,

, , ,,

. .: 20-40%

7.

, ,, (

),.

:

. .: 35-50%. .: 35-50% ( ) . .: 35-50%

. .: 20-40%. .: 20-40%

. .: 20-35%. .: 20-35%

( ) . .: 20-35%. .: 20-35%

. .: 20-35%


, :

. .: 20-35% . .: 20-35%

. .: 20-35%. .: 20-35%

, :

. .: 20-30%. .: 20-30%

. .: 20-30%. .: 20-30%

. .: 20-30%. .: 20-30%

8.:

1) . .: 20-30%2) . .: 30-50%3) . .: 50-67%4) . .: 67-80%

9.:

( , /)

. .: 20-30% ( , ,

). .: 20-30%

. .: 20-30%

. .: 20-30% ( , ,

Rett, Asperger) . .: 35-67%

10.

:


( ,)

. .: 20-30%:

, ,,

. .: 20-30% (

). .: 20-30%

:, ,

,. .: 20-30%

: / ,,

. .: 20-30% ( ): ,

,/ Gilles de la Tourette

. .: 20-40%

, , :

- . .: 20-30%- . .: 20-30%

. .: 20-30%- ( )

. .: 20-30%. .: 20-30%

/ . .: 20-30%/ . .: 20-30%


, ., .

, .:

1. ..

(gross) ,, (

, ), , ,

, , .2. .

, ,.

, .3. .

.,

, ,.

, .4. .

( , , ). , ,

, ,.

( , ADL). 14 . , .

( ) ( ,).

1 , 0 2 42 0 2 43 0 2 44 0 2 4


5 0 2 4

6 0 2 4

7 0 1 2 8 0 1 2

9 0 1 2

10 0 1 2

11 0 1 2

12 0 1 2 13 , 0 1 2

14 0 1 2

:. : 12

8, .. : 24

12 , .. : 24

12.

/,

,:

+ (1- )

( 0,35 35% ). =0,35 =0,20 55%

48%, 0,35+0,20(1-0,35) = 0,48. ( 10%), , (0,48)

(0,10), 0,48+0,10(1-0,48) = 0,53 53%.

.0 1 2 3 4


: 1-10% : 11-20% : 21-40% : 41-60%

: 1-5% : 6-15% : 16-30% : 31-50%

,

,

,

,

/

,

()( )

: 1-10% : 11-20% : 21-40% : 41-60%

: 0%

(

, , ) (

)

(

)

,


: 1-10% : 11-20% : 21-50% : 51-80%

0 1 2 3 4

(,

): 1-5% : 6-10% : 11-20% : 21-50%

( ,

): 1-5% : 6-15% : 16-20% : 21-30%

()

()

,

-

: 1-5% : 6-35% : 36-50% : 51-67%

,

-

, -

-

: 0%

: 1-5% : 6-10% : 11-15%


0 1 2 3 4

-

,

9-12

8

: 1-10% : 11-30% : 31-60% : 61-100%

,

: 1-5% : 6-10% : 11-30% : 31-50%

: 1-10% : 11-20% : 21-35% : 36-50%

,

- (GAF score 71-100)

,

- (GAF score 70-51)

,

- (GAF score

31-50)

70

,

-(GAF score 1-30)

: 0%

: 1-15% : 16-30% : 31-67% : 68-100%


0 1 2 3 4

( .

)

-

: 1-10% : 11-20% : 21-50% : 51-80%

15/10mmHg

-

,

2 ,

,

25/15mmHg

,

2 ,

30/20mmHg

,

2 ,

30/20mmHg,

: 1-10% : 11-20% : 21-50% : 51-80%

10 1515

-

: 0%

: 2% : 3-4% : 5-6% : 7-10%


-

(<5 0-

10)

(5-7 0-10)

(>70-10)

,

(

)

-

: 1-3% : 4-6% : 7-10% : 11-20%

:

.A. ( grade II

2007): 1. , , -

(primitive neuroectodermal tumors, PNETs) , grade III IV, ,

, .2. .

B. :1. .2. .

, ( , , ), ,

( . ).: 50-100%

( , ) ’.

80-100%

.,

,,

10% .

., ,

, , 80-100%.


.

, ,, ,

( , , ) . ,,

, ., ,

.

(ICD-10). G00-G99. ‘G’

. (0-9) 11 ( 3).

. ICD-10 ,

.:

(G00-G99)

:G00-G09G10-G13

G20-G26G30-G32G35-G37G40-G47G50-G59 ,G60-G64

G70-G73G80-G83G90-G99

: ( P00-P96 )

( A00-B99 ) , ( O00-O99 ) .

, ( Q00-Q99) , ( E00-E90 )

,


( S00-T98 ) ( C00-D48 )

, , ( R00-R99 )

:G01*G02* G05* ,

G07*

G13*

G22*G26*G32*

G46* G53*

G55*

G59*G63*G73*

G94*G99*

(G00-G09)

G00: }

} }

: } :

(G14.2) (G14.2)G00.0

(Haemophilus influenzae)G00.1 G00.2


G00.3 G00.8

: • [Escherichia coli] • Friedländer • [Klebsiella] G00.9 ,

: • ,• ,• ,

G01*:

• ( 22.8+ )• ( 54.8+ )• ( 27.-+ ) • ( 32.1+ )• Lyme ( 69.2+ )• ( 39.0+ ) • ( 52.1+ )• ( 02.2+ )•

• ( 50.4+ )• ( 51.4+ )

• ( 17.0+ )• ( 01.0+ )

: (G05.0* )

G02*

: (G05.1-G05.2*

)

G02.0* :

• ( 87.1+ )• ( 87.0+ )• [ ] ( 00.3+ )• ( 27.-+ )• ( 05.1+ )• ( 26.1+ )• ( 06.0+ )• ( 01.0+ )• ( 02.1+ )

G02.1*:

• ( 37.5+ )


• ( 38.4+ ) • ( 45.1+ )

G02.8*

: • ( 56.-+ )• Chagas ( ) ( 57.4+ )

G03: }

} }

}: (G04.- )

(G04.- ) G03.0

G03.1G03.2 [Mollaret]G03.8G03.9 ,

( )

G04 ,:

: (G93.3) :

• (G93.4)• (G31.2)• (G92)

(G35):

• (G37.3)• (G37.4)

G04.0 }

} G04.1G04.2 ,

G04.8 ,

G04.9 , ,

G05* ,

:


G05.0* ,

, ( ): • ( 32.1+ ) • ( 39.8+ ) •• ( 50.4+ ) • ( 52.1+ )

• ( 17.8+ ) G05.1* ,

, ( ):• ( 85.1+ )• ( 25.8+ )• ( 85.0+ )• [ ] ( 00.4+ )• (J09+, J10.8+, J11.8+ )• ( 05.0+ )• ( 26.2+ )• ( 01.1+ )• ( 06.0+ )• ( 02.0+ )

G05.2* ,:

, ( ):• ( 56.-+ )• Chagas ( ) ( 57.4+ )• (B60.2+ )• ( 58.2+)

( 83.2+)G05.8* ,

( 32.1+)

G06 ( 95- 97), ,.

G06.0 ( ):

• [ ] • • •

: • • • G06.1

( ) [ ]


: • • • G06.2 ,G07*

:

• ( 06.6+) • ( 54.8+)

• ( 17.8+) ( 65.-+)

: • ( 17.8+) • ( 17.1+) G08

: • } • } • } • } • }

: : • ( ): • ( 00- 07, 08.7) • , ( 22.5, 87.3) • ( 67.6)

(G95.1)

(G10-G13)

G10 Huntington Huntington

G11: (G80.-)

(G60.-) (E70-E90)G11.0G11.1

: 20 :

•• [ Hunt] •

Friedreich ( )


G11.2: 20 .

G11.3 DNA [Louis-Bar]

: Cockayne (Q87.1) (Q82.1)

G11.4G11.8G11.9 ,

/ ) / :••••

G12G12.0 , [Werdnig – Hoffman] G12.1

[Fazi -Londe] :•• ,•• , [Kugelberg-Welander] •

G12.2 - :

•• :••

G12.8

G12.9 ,

G13*

G13.0* (C00-C97+)

[Denny-Brown] (C00-D48+)G13.1*

(C00-D48+)

G13.2* ( 00.1+, 03.-+)

G13.8*


.

(G20-G26)

G20 Parkinson

Parkinson : •••

G21G21.0

( ), , .G21.1

( ), , .G21.2

( ), , .G21.3G21.8 .G21.9 ,

G22* ( 52.1+)

G23: (G90.3)

G23.0 Hallervorden-Spatz

G23.1 [Steele-Richardson-Olszewski]G23.2G23.8

G23.9 ,

:

: (G80.3)G24.0

(), , .

G24.1

G24.2


G24.3 : (M43.6)

G24.4

G24.5 G24.8 G24.9 ,

G25G25.0

: (R25.1)

G25.1 ( ),

, .G25.2

G25.3

(), , .

: (G51.4) (G40.-)

G25.4 (

), , .G25.5

: (I02.0)

Huntington (G10) (I02.-)

Sydenham (I02.-)G25.6 ( )

(

), , .: de la Tourette (F95.2)

(F95.9)G25.8

«»

G25.9 ,

G26* .

(G30- G32)

G30 Alzheimer


: :• (G31.1)• (F03)

(R54)G30.0 Alzheimer

: 65G30.1 Alzheimer

: 65G30.8 AlzheimerG30.9 Alzheimer,

G31 ,

: Reye (G93.7)G31.0

Pick

G31.1 ,: Alzheimer (G30.-)

(R54)G31.2

:•••

••

G31.8 [Alpers]

( ) Lewy ( )( )

[Leigh] G31.9 ,

G32*

G32.0*

:12 ( 53.8+)

G32.8*

(G35- G37)


G35 ( ):

•••••

G36: (G04.8)

G36.0 [Devic]

:(H46)

G36.1 [Hurst]G36.8G36.9 ,

G37G37.0

Schilder: [Addison-Schilder] (E71.3)

G37.1G37.2 .G37.3

:(G35)

[Devic] (G36.0)G37.4G37.5 [Baló]G37.8

G37.9 ,

(G40- G47)

G40: Landau-Kleffner (F80.3)

(R56.8) status epilepticus (G41.-) Todd (G83.8)

G40.0 ( ) ( )


-

G40.1 ( ) ( )

G40.2 ( ) ( ).

,

G40.3( ):

•• ( )

[ ] grand mal

:••

:•••••

G40.4 :

•• -

Lennox-Gastaut Salaam

WestG40.5

[Kozhevnikof]

:••••• stress

G40.6 grand mal, ( petit mal) G40.7 Petit mal, , grand mal. G40.8

G40.9 ,


( ):•••

G41 Status epilepticus [ ]G41.0 Grand mal status epilepticus

status epilepticus ( ): [ Kozhevnikof] (G40.5)

G41.1 Petit mal status epilepticus status

G41.2 status epilepticus ( )G41.8 status epilepticus ( )G41.9 Status epilepticus ( ),

G43

( ), , ,.

: (R51)G43.0 [ ]G43.1 [ ]

:••••• :•••

G43.2 (status migrainosus)G43.3G43.8

G43.9 ,

G44:(G50.1)

(R51) (G50.0)

G44.0


: ••

G44.1 ,

G44.2

G44.3G44.4 ,

( ), , .G44.8

G45: (P91.0)

G45.0 -G45.1 ( )G45.2 [ ,

, ]G45.3G45.4

: (R41.3)G45.8G45.9 ,

G46* (I60-I67+) G46.0* (I66.0+)G46.1* (I66.1+)G46.2* (I66.2+)G46.3* (I60-I67+)

:• Benedikt• Claude• Foville• Millard-Gubler• Wallenberg• Weber

G46.4* (I60-I67)G46.5* (I60-I67) G46.6*


(I60-I67) G46.7* (I60-I67*)G46.8*(I60-I67)

G47: (F51.5)

(F51.-) (F51.4) (F51.3)

G47.0[ ] G47.1 [ ]G47.2 -

. -

G47.3:

••

: Pickwick (E66.2) (P28.3)

G47.4G47.8

Kleine-Levin G47.9 ,

,(G50- G59)

: ,-

} } (M79.2)

(O26.8) (M54.1)

G50: 5

G50.0

G50.1G50.8G50.9 , .

G51: 7

G51.0 Bell


G51.1: (B02.2)

G51.2 Melkersson Melkersson-Rosenthal

G51.3G51.4G51.8G51.9 ,

G52 [ ]: :• [8 ] (H93.3)• [2 ] (H46, H47.0)

(H49.0 - H49.2)

G52.0 1

G52.1 9

G52.2 [10 ]

G52.3 12

G52.7

G52.8G52.9 ,

G53*G53.0* (B02.2)

: ••

G53.1* (A00-B99+)

G53.2* (D86.8+)G53.3*(C00-D48+) G53.8*

G54: -

(M50-M51) (M79.2)

:• }


• }• }(M54.1)• }

) } }

(M47.-) G54.0

G54.1G54.2 ,G54.3G54.4 ,G54.5

Parsonage-Aldren-Turner

G54.6 « » .G54.7 « » .

G54.8G54.9 ,

G55*G55.0*

(C00-D48+)G55.1*

(M50-M51+)G55.2* (M47.-+)G55.3* (M45-M46+, M48.-

+, M53-M54+)G55.8*

G56: –

G56.0G56.1G56.2

G56.3G56.4G56.8

G56.9 ,

G57: –

G57.0: :


• (M54.3)• (M51.1)

G57.1

G57.2G57.3

G57.4 BG57.5G57.6

Morton G57.8

G57.9 ,

G58G58.0G58.7G58.8G58.9 ,

G59*G59.0* (E10-E14+

.4) G59.8*

(G60- G64)

: (M79.2) (M79.2)

(O26.8) (M54.1)

G60G60.0

:. Charcot-Marie-Tooth . Déjerine-Sottas

, I-IV

( ) ( ) Roussy-Lévy

G60.1 RefsumG60.2G60.3G60.8

Morvan Nelaton


: ••

G60.9 ,

G61G61.0 Guillain-Barré

( -)G61.1

( ), , .G61.8G61.9 ,

G62G62.0

( ), , .G62.1G62.2

( ), , .G62.8

(), , .

G62.9 ,.

G63*

G63.0*

( ):• (A36.8+)• (B27.-+ )• (A30.-+ )• Lyme (A69.2+ )• (B26.8+ )• (B02.2+ )• , (A52.1+ )• , (A50.4+ )• (A17.8+ )

G63.1* (C00-D48+)G63.2* (E10-E14+ .4)G63.3* (E00-

E07+, E15-E16+, E20-E34+, E70-E89+)G63.4* (E40-E64+)G63.5* (M30-M35+) G63.6* (M00-M25+,


M40-M96+) G63.8* (N18.8+)

G64

(G70- G73)

G70: (A05.1)

(P94.0)G70.0

( ), , ,.

G70.1

( ), ,.

G70.2G70.8G70.9 ,

G71:(Q74.3) (E70-E90) (M60.-)

G71.0:

• , , Duchenne Becker

• [Becker] • [Emery-Dreifuss] ••••••• [Duchenne]

: :. (G71.2). (G71.2)


G71.1

[Steinert] : •••

:•• [Thomsen] • [Becker]

[Isaacs]

( ), , ,.

G71.2:

• .•

:•••

:• ( )•

G71.3 ,G71.8G71.9 ,

G72: (Q74.3)

(M33.-)

(M62.2) (M60.-) (M33.2)

G72.0

( ), , .G72.1G72.2

( ), ,.


G72.3 ( ):

••••

G72.4 ,G72.8G72.9 ,

3.10.4.

G73*

G73.0*:

• (E10-E14+ .4) • [ ] (E05.-+)

G73.1* Eaton-Lambert (C80+)G73.2* (C00-D48+) G73.3*G73.4*

G73.5* :

• (E21.0-E21.3+)• (E20.-+)

(E05.-+)

G73.6*:

• (E74.0+)• (E75.-+)

G73.7*:

• (M05-M06+)• (M34.8+)• Sjögren (M35.0+)• (M32.1+)

(G80- G83)

G80: (G11.4)

G80.0 ( )

G80.1 ( )


( )

G80.2 ( )G80.3

G80.4G80.8

G80.9 ,

G81: ,

( ) ( ),

.

.: (G80.-)

G81.0G81.1G81.9 ,

G82: ,

( ) ( ),

.

.: (G80.-)

G82.0G82.1G82.2 ,

G82.3G82.4G82.5 ,

G83: ,

( ) ( ),

.


.: ( )( ),

G80- G82 G83.0

( )

G83.1

G83.2

G83.3 ,G83.4

:(G95.8)

G83.8 Todd

G83.9 ,

(G90- G99)

G90:

(G31.2)G90.0

G90.1 [Riley-Day]G90.2 Horner

Bernard(-Horner) G90.3

[Shy-Drager] : (I95.1)

G90.4 .G90.8G90.9 ,

G91:

:. (Q03.-). (P37.1)

G91.0G91.1G91.2G91.3 ,


G91.8G91.9 ,

G92

( ), , .

G93G93.0

,

: (P91.1) (Q04.6)

G93.1 ,: :• (O00-O07, O08.8)• (O29.2, O74.3, O89.2)• (T80-T88)

(P21.9)G93.2

: (I67.4)G93.3

G93.4 ,: :• (G31.2)• (G92)

G93.5 } }

( ): ( ) (S06.2). (S06.3)

G93.6: :• (P11.0)• (S06.1)

G93.7 Reye

( ), , .G93.8

( ), ,.

G93.9 ,

G94*G94.0*(A00-

99+)


G94.1* (C00-D48+)G94.2*G94.8*

G95: (G04.-)

G95.0G95.1

( )()

: , (G08)

G95.2 ,G95.8

:••

( ), , .: :• (N31.9)• (G83.4)

(N31.-)G95.9 ,

G96G96.0

: (G97.0)G96.1 ,

( )( )G96.8G96.9 ,

G97

G97.0G97.1G97.2G97.8G97.9 ,


G98 ,

G99*G99.0*

(E85.-+) (E10-E14+

.4)G99.1*

G99.2*

(M47.0+) :• (M50.0+, M51.0+)• (C00-D48+)• ( 47.-+ )

G99.8*.


1. ( . . . Klippel- Feil,

, . .) ( , , . .),( , . .), ( . .)

( , . .) –

,.

,.

( ).

,

.

1.1. 0%

1.2. ( ,,

)

10%

1.3. ( ,

15 ,

)

20%

1.4.( ,

, )

30%

1.5. 30%- 40%

1.6. 50%

1.7. 67%


,

.

.

2.

2.1. 0%

2.2. ()

10%

2.3. ( . .)

20%

2.4. 30%

,.3.

3.3.1

,.

3. 1.1. >80%

3.1.2. >80%

3. 1.3. ( ) 80%

3. 1.4.. 67%

3. 1.5. 50%

3.1.6. 25%

3.1.7. 40%

3. 1.8. 30%


3.1.9. ()

10%

3. 1.10. ( ) 30%

3..1.11. 30%

3. 1.12. 25%

3.1.13. 40%

3. 1.14. + + V 40%

3. 1.15. 30%

3. 1.16. 50%

3. 1.17. 40%

3. 1.18. 50%

3. 1.19. 80%

.

. .

3. 2 -- -

. « », « ».

( , , ).

..

3.2.1. 0%

3. 2.2. 10%

3. 2.3. 20%- 30%


3. 2.4. >6 > 20 >20

10%

3. 2.5. 10%- 20%

3. 2.6. >15 > 3 5%

3. 2.7. 10%

3. 2.8. – )1-5 ,) ) , , )

0%10%25%

3. 3.

.

3. 3.1. ( 30, 45, 20)

30%

3. 3.2. 40%

3. 3.3. - :) >90 >20 ) <90, <20

10%20%

3. 3.4. 10%

3.3.5.20%40%

3..3.6. (80-100 , - ) 25%

3. 3.7. 40%

3. 3.8. -) <60, 120 ) >60, 90 (

- )

10%

20%-25%


3.3.9. 30%

3. 3.10. 20%

3. 3.11. 10%

3. 3.12.

.

15%30%

3. 3.13. (30 ) 0%-10%

3. 3.14. 20%

3. 3.15. – , ,10%-20%

3. 3.16. 0%

3. 3.17. 10%

3. 3.18. 5%-10%

3. 3.19. , ,

.

3.3.20. , : ’( )

) (15%) ) (10%) ) (10%)

0%-35%

3.4.

3. 4.1. ( ,)

67%

3. 4.2. (Duchenne-Erb) 50%

3. 4.3. (Klumpke) 50%

3. 4.4. 20%


3. 4.5. 10%

3. 4.6. 15%

3.4.7.)) ( )

30%20%

3. 4.8. 25%

3.4.9. ( )

( )35%15%

3. 4.10. 40%

3.4.11. 50%

3. 4.12. 50%

3.4.13. 50%

. () 10%.

3. 5. .

.

3. 6. .

, , , ,.

,.

4. .4.1.

4.1.1 >80%

4.1.2( )

80%


.

4.1.3 67%

4.1.4 67%

4.1.550%70%

4.1.6 Chopart ( ) Lisfranc ( )

30%50%

4.1.7 10%

4.1.8 15%

4.1.9 5%

4.1.10.

10%

4.1.11 15%

4.1.1220%30%

4.2. - - -

- -.

( , , ).

4.2.1 50%

4.2.2 30%

4.2.3. 2 .3-45-66-10

0%10%20%30%


>10 , ( )35-50%

4.2.4 – )1-5 ,) ) , , )

0%

15%

25%

.

4.3.

43.1.( 15, 0-10 0) 35%

4.3.2. 50%

4.3.3. 70%-80%

4.3.4. -) : > 90

-10%20%

) : < 90 ,

30%40%

) : 40%

60%

4.3.5. - 50%

4.3.6.20%40%

4.3.7. - -


10%15%

4.3.8. (10-15) 30%

80%

40%67%

4.3.9. -) : 0-120 , , 5%

10%

) : 10-90, , ,15%30%

: 30-90, ,

20%40%

4.3.10.20%40%

4.3.11. ( )

( - ) 10% .

0%10%

+10%

4.3.12. 10%

4.3.13. 10%

4.3.14. ( ’ ) 0%-10%

4.3.15. 15%

4.3.16. ( -, ) 5%-10%


4.3.17. 15%

4.3.18.

( ,, )

20%-35%40%

4.3.19. - 5%-10%

4.3.20. ( , ) 0%

4.3.215%15%

4.3.22.0%10%

4.3.23. 0%

4.3.24. , ,10%-15%

4.4

4.4.1. 80%

4.4.2. 15%

4.4.3. 15%

4.4.4. 35%

4.4.5. ( ) 50%

4.4.6. 30%

4.4.7. 10%-15%

4.4.8. 30%


( ) ’ .

.

4.5 .

.

4.6.

,,

.

5.

( - ), ( - ).

5.1. 0%

5.280%67%

5.3 80% ’

.

6.6.1.

/ ,.

’,

, ( , , .)

< 120 30%-40%


6.2, , .Paget :

.


- -

1.

,

..

�……………………………………………………15%

( , )…………10-15%………20-40%

, ,……………………………………60%

2. – •

.�

,…………………………………………………………5-20%

•,

.

.� ……………………………………………5-10 % ( ,

)•

.,

.� ………………………………………………50%• – – – � …………………………………………20-30% ( ,

)

3.•

18% 7% .

,, .

. ( . )� …………………………………………50-70%•

.� …………………………………………20-30%• –


.� …………………………………………60-70%

4.

:) : 1) , 2)

,3) 4) ,5) , 6) .

• ( )

. ,.

.� …………………………………………20-30 % ( ,

)• –

. ..

� …………………………………………20-30 % ( ,)

• – – -

) : 1) , 2) , 3) , 4) .

� ………………………………………40-50% ( ,)

.• ( )

,

. .� ………………………………………………

( 5.2 - )•

, ,,

. ( , ).� ………………………………………………5-10%•

.� ( , ( 5.2 -

)


– ,

. ( –

- , , ) ( ), ,

,.

.

( ) , ,.

..

.. 3

5 ., , ,

,.

.:

• .,

, – ..

20-30 ,, , .

.• ( - ).

,.

( ).: ( ), ( ),

( ), , ( , ,), , , , .

. . Meniere.

( ).

• . .• ( , , ).

. ..

.


. ( )

, ( )..

() .

.

., ,

(discrimination score). dB , ,

, , .,

, . ..

, .

« »( ).

�• , :

, .• ,

………………………………………………………………………0% ………………………..……………………………………………5-10% ……………………………………………………………………10-15%

………………………………………….…………15-20%…………………………………………………………………20-25%

:

I II III IV V VI

I. 0 0 5 10 20 25

II. 0 10 15 20 25 30

III. 5 15 20 25 30 35

IV. 10 20 25 30 40 45


V. 20 25 30 40 50 60-70

VI. 25 30 35 45 60-70 70-80

.. . 80%

,:

<40% +8% 40-60% +5%

.

. >60% +3%

: +5%

+3% ( – ) +5-10%

+15-60% ( . 5.1.1.) +30% ( .5.3.6.)

+5% +205 ( .5.1.2.)

- ( ) +40%

., ,

, , , , .,

, .. ,

, ,.

,, , ( ),

(MRI) -. MRI

( « »,

.

.


: 1) , , , 2) , 3)

, 4) , 5) , 6) , 7)

, 8) , , 9) , 10) , 11)

, 12) , 13)( , , , ), 14) ,

.

1. Meniere ( ), ,

, ,.

3 :- : , , .- : , , .

.- : ,

..

..

( ,)

(4-5) .,

..

..

.� ……………………………………….60-70%

2.

Meniere - : , .- :

.- .

…………………………………………60-70%3.

Scarpa

.• -


. 1-2 ..

� ………………………………….…30-40% ( )

4..

/,

. ..

,.

� ………………………………………………20%.

. ( , , . .). .

., , 6 2 .

� …………………………………………..20-30 %

5 Meniere .

.� ………………………………………….35-40%

6.•

.. .

, .•1) ( - ,

. . , 2) 3) .� …………………………………30-40%• -

.

( ).,

., .

.

.,

. . .


( + ) ( + ) 20% .)

>20%.

( ) ..

. ( )

. , ,. .

-

: ) , ), ) ( ), ) .

1..

,* –

.

…………………………………………………...10%

2..

.* –

, ..

- ………………………………………………..…….……10-15%- …………………………………………..……….…20-30%- …………………………….… …………….………………..10%- (

)………….……………….….…………….…30% - (

)…….………………………………..…...40%


3.

.* –

.

……………………………………………………………………….………..0%

4.* –

.

………………………………………………………………………..……..0%

5..

. – - –

–

…………………………………….…….……….10%

6. ( ).

( , , , ).* –

………………………………………………………………….........................…….……..30%

7..

.* –

.�

…………………………….………………..…………....…………10%

8.

………………………………..………………………………………….…..10%

9., , , Wegener

, .

10. .


.

–

CT* –

.

……….………………..……………………..10-15% ( ,

).

1.* –

.�

( )…………………..….…..10-15%

………………………………………………….…………30%

12.

* – .

…………………….………………..……….…..10%

13.

- : 30% ( , , ). ( , ,

, Rendu – Osler – Weber). * –

.

…………………………..…………………………….…………....…..10-40%

14.•

1. 2. 3, 4. 5, 6. .

* – .

�………………………………………….…..……………...……10-30%

. . , , .


•1. 2.

3. 4. 5. 6. 7. 8.

* – C.T. –

* – , (

– .)., , .

, ,.

�………………………………………………….……………….70-80%

5/ 30% 1, 4, 5, 6 .

-

1. –

.�-…….……….……..…………………….……..50%-.…………………….…………….………….……5-10%-..……………………….…………………………..……5-10%- ….

)…………………….………40%

) ( )

…………………......60%-( , )… ………………………………….…20%-

...........………………………...………20% - ( - )- ,

……………...……………………………………..…………………………..……5-10%

2. - - -


•�

……………………………….……………...……….50%

………………….…..………..….15-20%

. ..20-30%

• ( )�

……………………….………………………….……50% ( )

( - )..

..………………………………..….20-30%

3..

•* –

�………………………………..……………….10%

•

* –

�…………………………...………..….15-20%

•

1. 2.* –

– -, ( . )

1,2 , 3. 4. 5. .

. � ……………………………..…..…….60-70%

1 2 ’ -�……………………………….………….80%


4. -

•1. , 2. , 3. , 4. , 5. ,6. .* –

, . ( ) :

.* –

– – �……………………………..………………..40%

•1. , 2. , 3. on Hodgkin .* –

– -, - (

20% ) �……………………..….…………..……..70-80%-

1. , 2. . 5/ 20% 1 , 2 40%

* – .

� ………..………….………..…….…….80%-• : .• : , .• : & , ,. , C.T. , M.R.I. .* –

. - .� ……………………………….. ………..………….…………….80%

1.( , , , )

( ) .• –

.- .


�-……………...…...……10-15%-…………………..……....……10-15%-………………………..….……20-30%-

……….…………………………………….………………………………..……60-70%-.……………..………..…50-60%-…………………………………………..…...………30%-

…………………………………………......…….....………40%

2.* –

�……………………………………..……………...….…………60-70%

3 -.

.* –

, .-…….…….……………..……….…20-30%-………………..….40-50%

4..

.• -

.�

……………………………..…………………………..………….….…20%

5. – REINKE

..

• -


�………………………………………..0-10%

6..

.• -

�…………………………………..…………..0-10%

7.• -

.�

………………………………………………………………..……..10-20%

8..

.• -

.� ………………………………………………………..….10-20%

.9.� ………………………………………………………..….10-15%

10.( , , . .)

,.

�1.

…………..….10%2.

...…………..20% 3. …35-45%

11..

( . . , , , , ).

• : 30% 70% • : • : & , ,

, C.T. , M.R.I. .


• .:1( 1, , ) . .• –

. ( laser) ..

2( 2, 1, ) .

, , , . –

. ( ) .

3( 3, 2. ) ,

, , 3 ., , , .

• – ( ). . ( ).

: 1) , 2) , 3) .

4( 4, 3, 1) .

.. , , ,

.• –

. . . .� ……………………………………………………………….70-80%• -

,. ’

maximum 1 – 2 . ( ,, , , )

, .

12�

……………………………………………………………………..……….20%

……………………………….……………………………….…50%…………………………………………………………50-68%

……………………………… ………………………..……..….60-70%


13.• –

. 1) , 2) , 3) .• –

�..…………………..……………………….20%• -• –

.� ……………………………………….20-30 %

..

. 2 : 1. , 2.

, 3. , 4. - - - .• : ( ) BERA (

), , C.T. , M.R.I. - – .

• : & , ,, C.T. , M.R.I. .

• – �

.

, , , . (BROCA) (

WERNICKE ) ,.

• : , , , BERA, C.T. , M.R.I. – .

• –

� ………………………………………….…………….20-30%

( ).


. . ..

• –

�……………….………………..….10-20%

., .

: , .• –

. ,.

�……………….…………..……….10-30%.

..

.• –

� …………………………10-20%

.

. , ( ) ( ).

• – –

� ……………….….…………10-30%


1.

1.1... , . . , ,

, , ., , (Wermer 1, Sipple 2)

.. , . . ,

( ), ,

1 2. . ,

,. ,

.

.1

,.

• –

, . . , , .� …………………………………………….0%2

, . ., , ,

.T .3K .• –

,,

, .� ………………………………………0%

,, .

,:

� ………………………………………60-80%


,( , ).

1.2... . . -

Zenker, , , ( ), , ,

Barrett .

. . . ().

..

1

, . . , ,.

• – .

� …………………………………………0%2

( . ., ,

)

� ……………………………………………0-10%3

.,

.• –

.� …………………………………………67-80%

, . .=60% . . =50%. .=30% .

1.3.1) : – ,

.� ………………………………………………0%2) : –

.� ……………………………………………0-20%3) :

– – – - .� ……………………………………………30%-50%

.4)


• – .

:� ………………………………………………67% 6 ,

( ) 1 , ,

. 5 .

:� ………………………………………………67-80%5) , ,

( ), .

� …………………………………………30%6) :

7) ), ) , )

,.

� ………………………………………10-20%8) Dumping ( ):

. ……………………………………………20-30%

9) : 8-12 20%

.� ………………………………………………20%

1.4. .:

, , ,, , , ,

Hirschsprung. – , - ,. .

1/3 . ½ 330 ,

80% , 500 ,.

1) 3 ,, .

� ………………………………………………35-55%2) :

..

� ……………………………………………0%


3) 12/ : - -.

:� ……………………………………………0%4) 12/ : , 12/

.:

� ……………………………………………0% (

) ,:

� ……………………………………………30%5) : ,Billroth II – ( ).

,.

.� …………….…………………………40- 50%

………………………………………………0% 6) :

.� ………………………………………………50%7) :

, :� ………………………………………………50%

.� ………………………………………………30-50%

1.5.. ( , Crohn,

, Gardner, Peutz- Jeghers). ( , ,).

. ( , ,).

. – .

1.

• -.

� ……………………………………………0%2Y (>50%) -(100%) ( , . . .)

:� ……10%-30% 50%

.


3

� ……………………………………………30%-50%4

• – .

:� ………………………………………………67% 3 ,

( ) 1 , ,

. 5 .

, . .

:� ………………………………………………80%

1.6.

))) , 12/ ,)

.� ……………………………………………0%

) .� ……………………………………………0%

) : – –

.� ………………….……20%[1 ]

1.

(100-200 . ./24 )..

� …………………………………………10%2

. 300 . .. 12/ .

.� ………………………………………20-40%

12/ , Vater,

. :� …………………………………………50-80%


.

1.7. ( )

:1.2.3.4. .

.

1.

.• –

.� ……………………………………………0%2

,

( ).� ……………10-30%[1 ]3

,. ,

( ) .� ……………50-80%[2 ]

( .1.1.2.).

1.8.. . . , , , ,

. ,, , , Caroli,

. .. . . ,

.

1, . .

, .• –

.� ……………………………………………0%2

( , ).

• -


� ……………………………………………20-40% (6 )

3, ,

: « »4

– . ( / )

. . ,, , . .

• –

� ……………………………………50-80% ,>80%

1.9. – – - –

1

• – .

� ………………………………………0%: :

� ………………………………………0%2

, ,

. ,, .

, ,

( 3) () :

� ……………………………………………………20%. :

� ………………………………………………...10- 30% /

30-40%

1.10.

1. ( ), , ( Gardner), Zollinger-Ellison ( ),

, (WDHA )/ .

2. , ( . .).


( . . ,, , . .) ( . . Gardner,

Turcot, )

.

1 (

). ,. , Peutz-Jeghers.

• – .

� …………………………………………0%2

, , ( . . )

.• –

� …………………………………………20% (1 )

3, . .

( ), Gardner (

). , . . ,, .

• – , .

� …………………………………………50%-80%

2.

2.1. –

, ( - - - . .).

1.1.4, 3.9.2..

1, ,

.• –

, .� ……………………………………………0%2


, ( . . – ) ( . . )

.• –

1-2 . (

).� ………50% [1 ]

……………………………30-50% 60%[2 ] 2

3, . .

. ( . ),

.• –

. , 1-2 .

, ( 2 ).

� ……………………………………….40-67% [2 ]. .

.- ……………………………………………………30%

2.2.: 1)

( ),. 2) (

- - ).

1

• – .

� ……………………………………………0%2

– – -- - (

).� …………………………………………10-20%3

. ( – – ) .

. ,,

.


� …………………………………………30-50%

2.3. Raynaud

( ) .

1.

� ………………………………………………0%2

.� ……………………………………………..20-30%3

.� …………………………………………..30-50%

2.4..

. ( - ).

. – .

1.

� ………………………………………………10-30%2

- ..

� ………………………………………………30-50%3

– 50 ..

� ………………………………………………50-67%4

- – ..

� ………………………………………………67-80%

50% 1

2.5.: , .


: , ,- ( )

: , .

1.

. .2

– ,� ………………………………………………20-50%3

-.

� ………………………………………………40-67%4

– , ,

� ……………………………………………67-80%……………35-50%

. .

2.6. -1) ( ),

( . .), ( . .

),, , . . ,

.2) ( , ,

, , . .).

. ( . . Doppler, Triplex ),

- .. .

, ,.

1,

., ,

( . .).

(amaurosis fugax) .

• –


,.

.� ………………………………………………0-10%

2

,,

.•

..

, ,, .

. . .�

3,

.

• – . ,

. .� …………………………………………67-80%

………………………………………67%

50%……………………………………………10-20%

>50-100% ……………………………………………50-80%

[ , ]

……………………………………….......30-50% 1

<5cm ………………………0-10% >5cm ………………………50-80%

/…………………………………………….35-50%

.


3.

. : – - , ,, .*

. ( ),.

1 ( , , ).

• – .

�. .

* ’ ¨ ¨

2 ( – -

) .• –

.� ……………………………………………0%3

( ). (),

, , .• –

.:

� ………………………………………………67% 3 , ( ) 1

, ,.

5 .:

� ………………………………………………67%-80%

. :� ………………………………………………30-50%


-,

.

.

.,

:. (30 - 50 ml/min) 25% . (15 – 30 ml/min) 50% . (< 15 ml/min.

) 67-100% .

. 1 >80%

. 50 - 67%

..

- ( - - ). 1/3

..

,. 1 40% . 1

. 25% ( )

. . 67-100%

. ..

.

(RF- )

. 1 40%

. 1. 25%

( )


. . 67-100% . ..

.

.

. ,

,.

.

. 1 40%

. 1. 25%

( ).

()

. . 67-100% . ..

( ) ( – -

).

., ,

.

. 30%

. 10% .

-

( -)


.(

). .

( ) ..

. 0%

.

.

/ /

( ) ( .) ( .

) ..

( . , ) .

.. ,

,

..

rmond

( ).

( . , ).

.( ) . 15%

. ( )

..

50% .

. 67-100%


.

- ..

..

.. ,

,, .

..

0% .

.

..

.

..

0% .

..

50%

. PSA .

15 .

.

..

.. 25%


. ( , ,) 25%

. 40%

.

67-100% . 67-100%.

. 80-100%

..

.. 3 .

, , .

.

..

.

. ( ) ,

. ( –

). .

..

.

. ..

15-25% .

25-35%

10% .

. ( )

. 40-80%


10% .

..

80-100% .

67-100%

..

.

.

,,

,.

( )

. International Continence Society (ICS)

. . ( ) (

). .

. .

. .

..

20% . ,

1.

.


30-67%

40. .

.

,. 2

.,

..

/ 30%

. . 15% . /

67-100%

. . 15-67%

. 5%

50 40%

50

30%

. .

. 40%

. 67%

. 67-80%

. 67-100%

.

40%


.

.

., .

.

<60 30% >60 20%

40% PEYRONIE

Peyronie 1/3. 10%

.

..

. , (),

..

. , 0%

. ( ) 5%

..

10% .

. 15%

., ,

. ,. ,

, , . .

.

.


40-80%


( ),

.

.:

5/10 4/10 3/10 2/10 1-2/10 1/10 1/20 < 1/20 5/10 0 5 10 10 15 20 25 25 25

4/10 5 10 15 15 20 20 30 30 35 3/10 10 15 20 30 35 35 40 45 45 2/10 10 15 30 30 35 40 45 50 55 1-2/10 15 20 35 35 45 50 55 60 60 1/10 20 20 35 40 50 60 70 85 85 1/20 25 30 40 45 55 70 85 90 95 < 1/20 25 30 45 50 60 85 90 95 100

25 35 45 55 60 85 95 100 100

:

(%)

300 5 20 100 10 80

5 10 25 50

25 30

50 * 10 ( )* 25 ( )

* 3 , 2 10%


(%) 50

70 30 70

:,

.

: ( )

,. : 90% 1/20

. «», ( ).

,

..

, ,

. , ,:

o ( )

: : 35% - : 50%

o ( ,)

: : 35% - : 50%

o: 50% ( 1 ) - 80% ( )

o -

: : 15% - : 30%


o -

: : 25% - : 50%

o ( 1 ): : 67% - : 80%

o ( 1 ): : 35% - : 80%

o ( )

( 1 ): : 20% - : 50%

o ( laser)

( 1 ): : 25% - : 50%

o lattice

( 1 ): : 10% - : 40%

o: 50%

o: 10%

o: 67% ( ) – 30% ( )


,, , ,

.

1.

-, , , , ,

.

1,

, , / , Raynaud, . . ’

,.

,

• – .

, .

�……….....50-67 %

2,

( , , ), ( , , , ),

( , , ), ( , ,), ( , ), .

• –

, .

-

�

, ......................>67%

( . , ,, . . .),


( , ) ( . )

2.

-, , ,

. Raynaud.

( ) ( CREST) .

, ,( , ), , ,

.

• –

. , ,.

.

� 25 – 50%.

, . . >80%.

, >67% -100 % [3 - ’ ]

3. -

-, , .

. ,, , ,

, ( ,) .

.

• –

.

.

�


, , >67%. 20-40 %. 67-80% [2-4 ].

’.

4., ,

-

, ,,

( ,), .

,. ,

.

• – ,

, 2/3 ,

. ,,

, .

.

50-67 %..

./ . .

..

, >67% -100 % [3 - ’ ].

. .

5. ( ,, - , Wegener,

Kawasaki, Churg-Strauss Henoch-Shonlein, Behcet’s)

-


, , ,,

( -Behcet’s ), .

..

• – / ,

,.

- , . .-Behcet’s,

,-Behcet’s . . .

�

.......................>67%

( . , , ,, . . .)

( . ).

6..

,.

.. .

/ . .

7.,

..

,

( . ).

8.

., )

( . ), )


( .).


1..

• – . .: « ».

2..

.: « ».

3. ( , ,

) . –

..

: « ».

4. ( , Grawitz, )

,.

8%. ( , , ,

, , , ) 10-40% .

– 5 45%.

65%.

-……………………..50-67%

( ….20-30%) - , , …...80% 80%

5.

. –

.: ( ,

/ , )… 20%, … , .

6.


. : 3 ,/

( , (>300mg 24 )) / ( ) / GFR < 60 mL/min/1.73 m2

3 . (e-GFR) :

1 : Cockcroft and Gault eGFR={(140- ) x )/(72 x mg/dl)} x 0,85

MDRD Study equation eGFR = 186 x ( mg/dl)-1,154 x ( )-0,203 x (0.742

) MDRD Cockroft and

Gault ..

. 1 2 ( 90 ml/min 60-89 ml/min )

. …. 0%

3 ( 30-59 ml/min)

…10-20% 4 ( 15-30 ml/min)

, , , , .

.…35-67%

5 ( <15 ml/min) …80%

( )

<15ml/min – … 80%

7.: ,

, ..

- ………………. 80% [2 ]- …………… 50 - 67%- / …80%


. , .

, ,

.,

,,

, ,,

. ,, , .

,

. ;

,. ,

, , ,

.:

.

.

.

.

1.

FEV1. –

( ) .................................................................35 – 50% (2 )

2

,. FEV1

, .


–

. ................................................................50 – 67% (2 )

3

,, FEV1 30% . FEV1 >30% .

. , FEV1, .

–

', , .

...............................................................80% ( ' ).


E

1..

Pb. .

1

Pb <40 mg/100ml, -ALA 0,6 mg/100ml • –

,.

.…………………………… 20%

2

, .

Pb 40-80 mg/100ml, -ALA 0,2 mg/100ml. ( b)

• – ,

(3 ) .…………………20-50% [3 ]

3

, , .

Pb 80-120 mg/100ml, -ALA 2-4 mg/100ml. • –

. EDTA .

� …………………50-67% [1-2 ]4

, , , , , , , ,.

Pb 120 mg/100ml, -ALA > 4 mg/100ml. • –

..

…………67% [2-3 ]

2..


..

1

, ., .

Hg .• –

.� …….........…… 35% [3 ]2

, , , , ,, . , .

, . ,. .

Hg . .• –

. BAL EDTA. …………50% [1-3 ]

3..

, , ,,

..

1

, , , .

. <10mg/L. • –

.� ………………….……… 20% 2

, ,. >10mg/L

.• –

,…………………20-50% {1 }

3 60%.


2_ 200-499 mg/L. • –

…………………50-67% {2 }4

, , .

500-999% mg/L. • –

..………67% { 2 }

4..

, .1

, ( ).

.• –

, .2

, , , , , .

- , ( ). .

• – . .

BAL EDTA. .………50-80% {1-3 }

5..

, , ,.

.1

, , , ,.

• – . .

.………20-50% {1-2 }• –


2

« », , , ,.

..………50-80% {1-3 }

6..

(AsH3, As). .

1

, , , .

, .• –

..…………………………..…0-20%

2

, , , , , ,, .

,• –

..…………..…20-67% {1-2 }

3, . .

; • –

, ,.

.……..…67% {2-3 }

7. ,.

.. .

1

, , , .• –

..……………...…0-50% {1 }


2

, ,.

• – .

.……...…67% {2 }

8..

clearence ,. .

.1

,, . , , ,

.• –

..……………….....…35% {6 }

2

, ,.

• – .

.…………....…35-50% {1-2 }3

.• –

, ..…………....…67-80% {2-3 }

9..

, . ( , ).

( , , ,), , .

.1

• – .

.…………....…2


,.

• –

..………………………….....…20-50%

3. ,

.• –

. ..………………………….....…67-80%

10..

..

.. . , , ,

, ,, , .

1. , , ,

.• –

. .� .…………....…2• –

..…………....…

3, .

.• –

..………………………….....…50-67%

11. -.

, , , , (

). , ,, , , , .

.1

, , .


• – .

.4

.………………………….....…5-20%2

, , .• –

. ( )……35-67%

12..

, , ,, , ( ), .

. .( , ,

)..

1, , , ,

.• –

.� .…..…10-50% { 6 -1 }2

. .• –

.� .……....…50-67% { 1-2 }3

, .� .……………………………..…80%

13. ( , , ).

,. .

,., ..

DNA ..

..


1

.� .……………………………..…0-35%

, ..

2, .

� .……………….…………..…67-80%

14. ( , ).

,, , .

(V, VI, VIII, IX XII) V . ,

..

.1

, , .� .………….………2� .……………....…35-50% {1 }

15..

: ). )

. ) .

., , .

. ..

.

., .

.

..

1, , , .

� .……………………….....… 35% . .

2� .……………………….....…35-50%


3, , .

� .……………………….....…67-80%

16..

,.

. , ,, .

..

.1

, , ().

� .………….………2

.� .……………………….....…50-80%

17..

, , , ,, , , , , , ,

, ..

18 ..

, , , ( , , ,). , ,

..

1, , , , .

� .………….………2

, , .� .……………..35-50% {1-2 }3

, .� .……………………………..50-67%

18..

..

..

1


. , .� .………….………2

( , )� .……………………………..50-80%2

19. - - -

..

(). -

- , , ,. , , ,

. , ,.

. , Heinz.

.1

, , , , .� .………….………

, , .� .……….50-67% {6 -1 }

20..

..

, .,

. 2,4- .

, ., , , .

.,

. ,.

.1

, , , .� .………….………� .…………………..50-80% {1 }2

. ( ).� .…………………..35-50% {1 }

1


..

• – .

.� .……...50-67% {6 -1 }2

• – , .

21..

10 ) 5.500 .

.

.,

.2

.

.1

.� .………….………

, , , , ..

• – .

� ……………..50% {6 -1 }3

� ……………………………...67-80%

22. -.

. ,

, ..

40 DB 1000, 2000 3000 z. 4000 z,,

.�


. . .

23..

8 10 m2 .

« ».

.

. ,, , ,

.

• – .

..

� ……………….…………….. 35% 2• –

.� ……………….…..50-67% {2 }3

, , . / : . A,B,C. : . :

.• –

- (). .

� …..80% {3 }� ……………….50-67% {2 }

, . . . /, A,B,C. ,

. (SiO2). (

(quartz), , , , .

). , , , ,, , , . .

. – . : ,

. ,


. , ,.

.

1

.,

. / 1-3 mm (p,q,s,t) 1-2. • –

. .� ………………………….20-50%2

. . ./ : 3-10 mm (r,u) 1-3 : (p,q,s,t)

3. ‘’’’. . :

. : .

• – .

,.

3

. : -. : .

., -

.• –

.� ....80% {3 }

(CWP) I. (CWP)

( . . ).,

..

.

,.

1

- .


- ,. : - . / :

1-3 (p,q,s,t) 0-2. :• –

.� .……………………………. 50% 2

- . « ».

: . . . : . : / : 3-

10 . (r,u) 1-3 (p,q,s,t) 3. 30 .

• – .

,.

� .………….……….50-67% {2 } « »

: .

, ,, ( ) ( ).

: 1. - . 2. . 3. . 4. ( . ).

Asbestos-Asbestosis - « »

.3

(PMF) 30 . . ILO A,B & C ( 30 .).

- , , ,, . : -

. : - .• –

. -. .

.� .….80% {3 }

. Caplan Caplan

..

2 . .. . . .

Caplan


, 50-80%.

, - ..

..

( ).

. –

..

..

..

..

1

. , .: . / : ,

. , (s,t,u, 1-2).

. :. . : .

• – .

. .� .………………………………….50%2

. – . : .. . . / :

(s,t,u/3). . :.

. : .• –

.� .…………..………….67% {2 }3

. – – . .:. . . . / : (s,t,u/3).

( ) ( 5 mm). . :

. . : – .


� ……..80% {3 - }

( « ») , .

. ( )

.1

G1/2 G1 G1/2: : G1:

– . :. :

( FEF 25-75 . . .) . . . : . ./ : .

• – . « »

.� ……………………………..10-20%2

G2 G2: – ( )

. - . :

. . . : –

. - . . / : . . : . .• –

., G3 .

� …………………30-40% {1 }3

G3 G3: –

: ( ). : .

: . / : . . .• –

G2- ..

� …………………50-67% {2 }

« ». 200

..


18 ..

5-10% .

. ( )

( ) ( ).

10-20 2 . 4-8 24-72 .

.

« ». 1)

. 2) 1-2

« » . 3) .

. « » . 4)

3 ( ,

) .. 5)

« » ( ).

(PEFR) (peak flowmeter).

.

: • : , , ( ,

), , ( , ), ( , . . .), ( , . . .).

• : , , , , ( ), , , .

• – ,

., .

. 80% (0) .

24.

. 15% 5%


.,.

, ,

( ,).

., , ,

..

,,

.

. , 80% .

., ,

.

. .

.

.

..

, , . .

..

Η απόφαση αυτή να δημοσιευθεί στην Εφημερίδα της Κυβερνήσεως.

Αθήνα, 31 Οκτωβρίου 2011

Ο ΥΠΟΥΡΓΟΣ

ΓΕΩΡΓΙΟΣ ΚΟΥΤΡΟΥΜΑΝΗΣ

pinakas_anapirias

Documents

international classification

viii ix

grand mal

50 mm hg

60 mm

peutz jeghers

alzheimer